Abstract

The protease ADAMTS7 functions in the extracellular matrix (ECM) of the cardiovascular system. However, its physiological substrate specificity and mechanism of regulation remain to be explored. To address this, we conducted an unbiased substrate analysis using terminal amine isotopic labeling of substrates (TAILS). The analysis identified candidate substrates of ADAMTS7 in the human fibroblast secretome, including proteins with a wide range of functions, such as collagenous and noncollagenous extracellular matrix proteins, growth factors, proteases, and cell-surface receptors. It also suggested that autolysis occurs at Glu-729–Val-730 and Glu-732–Ala-733 in the ADAMTS7 Spacer domain, which was corroborated by N-terminal sequencing and Western blotting. Importantly, TAILS also identified proteolysis of the latent TGF-β–binding proteins 3 and 4 (LTBP3/4) at a Glu-Val and Glu-Ala site, respectively. Using purified enzyme and substrate, we confirmed ADAMTS7-catalyzed proteolysis of recombinant LTBP4. Moreover, we identified multiple additional scissile bonds in an N-terminal linker region of LTBP4 that connects fibulin-5/tropoelastin and fibrillin-1–binding regions, which have an important role in elastogenesis. ADAMTS7-mediated cleavage of LTBP4 was efficiently inhibited by the metalloprotease inhibitor TIMP-4, but not by TIMP-1 and less efficiently by TIMP-2 and TIMP-3. As TIMP-4 expression is prevalent in cardiovascular tissues, we propose that TIMP-4 represents the primary endogenous ADAMTS7 inhibitor. In summary, our findings reveal LTBP4 as an ADAMTS7 substrate, whose cleavage may potentially impact elastogenesis in the cardiovascular system. We also identify TIMP-4 as a likely physiological ADAMTS7 inhibitor.

Highlights

  • The protease ADAMTS7 functions in the extracellular matrix (ECM) of the cardiovascular system

  • As tissue inhibitor of metalloprotease (TIMP)-4 expression is prevalent in cardiovascular tissues, we propose that TIMP-4 represents the primary endogenous ADAMTS7 inhibitor

  • As a source of endogenously expressed extracellular matrix substrates we used human fibroblasts. These were co-cultured with HEK cells stably transfected with either ADAMTS7-Mu or the inactive ADAMTS7-Mu(E389Q) for 48 h and the conditioned medium was used for iTRAQ labeling of new N termini that are generated by proteolysis

Read more

Summary

Edited by Ursula Jakob

The protease ADAMTS7 functions in the extracellular matrix (ECM) of the cardiovascular system. The analysis identified candidate substrates of ADAMTS7 in the human fibroblast secretome, including proteins with a wide range of functions, such as collagenous and noncollagenous extracellular matrix proteins, growth factors, proteases, and cell-surface receptors. ADAMTS7 is an extracellular metalloprotease and 1 of 19 human ADAMTS family members [1] It is a large protein (Ͼ250 kDa), consisting of 15 domains (Fig. 1A). It is essential to identify the physiological targets of ADAMTS7 to enable a causal link to be established between ADAMTS7 function and CAD/atherosclerosis To this end, we used terminal amine isotopic labeling of substrates (TAILS), which is a method that employs the labeling of neo–N termini generated by proteolysis to identify and quantify cleavage products by MS-based proteomics (LC-MS/MS) [16]

TAILS analysis
Discussion
Generation of expression vectors
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call